Stock Ratings / Health Care / IPSC / financials

LCTX (29) CABA (42) FATE (40) OCGN (35) ⌘ Pro Terminal →

Century Therapeutics Inc. (IPSC) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.46 -2.67% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.45

Century Therapeutics Inc. (IPSC) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $264.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.45 (-0.67%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-13.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IPSC)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (28/100 Composite)

🔍 WHY IPSC SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (46% of score)

FRED Regime × Technicals: 39% of 52W Range • RSI-14 at 44.7 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+7/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.47-6.8% Next Q

Q2 (-2Q)

Grade E$1.37+6.6% Next Q

Q3 (-1Q)

Grade E$1.46+0% Next Q

Current

Grade E$1.46-10% Hist 90D α

Trajectory: E (36) → E (28)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IPSC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IPSC currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.74) and Max Pain ($1.53) forces dealer call-delta covering toward $3.19.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IPSC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IPSC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 28%NO 72%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How IPSC Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $2.2M

FY24

Rev $6.6M

FY25

Rev $109.2M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$109.2M	52%	-15.8%	-$9.6M	-$104.7M	-14.1%
FY 2024	$6.6M	52%	-80%	-$126.6M	-$110.3M	-45%
FY 2023	$2.2M	52%	-80%	-$136.7M	-$88.3M	-14.1%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IPSC)

✓Walkthrough of IPSC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IPSC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -36.24%▼ DESCENDING CHANNEL

2026-10-30O $1.46H $1.50L $1.37C $1.46VOL 951.1K

RES: $1.92SUP: $1.01SMA50: $1.74SMA200: $2.10

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IPSC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IPSC Butterfly Map → + Track IPSC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IPSC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IPSC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IPSC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IPSC)

Health Care Rank #966 of 1016 ⚔️ LCTX vs IPSC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IPSC vs. LCTX, CABA, FATE, OCGN)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Century Therapeutics Inc. (IPSC) ranks #966 by composite RQD confidence (28/100, grade E) and #536 by equity capitalization ($264.4M). Within this direct 5-issuer industry benchmark cohort, IPSC leads on earnings valuation at N/A trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. CABA currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with IPSC at 28/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IPSC ACTIVE Century Therapeutics Inc.	E	28/100	—	—	-14.1%	-2.67%	$264.4M	Benchmark Subject
LCTX Lineage Cell Therapeutics Inc.	E	29/100	—	—	-35.0%	-0.96%	$260.5M	/lctx-vs-ipsc →
CABA Cabaletta Bio Inc.	D-	42/100	—	—	-35.0%	+4.28%	$268.7M	/caba-vs-ipsc →
FATE Fate Therapeutics Inc.	D-	40/100	—	—	-35.0%	0.00%	$260.0M	/fate-vs-ipsc →
OCGN Ocugen Inc.	D-	35/100	—	—	-35.0%	-4.15%	$252.4M	/ocgn-vs-ipsc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001850119

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Century Therapeutics Inc. (IPSC) reported GAAP revenue of $109.2M (+1556.8% vs. FY2024 revenue of $6.6M , and +4784.3% cumulative change since FY2023) , GAAP net income of -$9.6M, operating cash flow of -$103.9M, and free cash flow of -$104.7M (+5.0% YoY). On the balance sheet, IPSC closed FY2025 with $223.7M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$109.2M	-$9.6M	-$103.9M	-$104.7M	$223.7M	—
FY2024 (FY)	2024-12-31	$6.6M	-$126.6M	-$110.1M	-$110.3M	$353.2M	—
FY2023 (FY)	2023-12-31	$2.2M	-$136.7M	-$88.3M	-$88.3M	—	—

3. IPSC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IPSC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Century Therapeutics Inc. (NASDAQ: IPSC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $1.46 (-2.67% 1D, market cap $264.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IPSC ranks #966 in composite RQD confidence.

How does IPSC compare to LCTX and CABA in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IPSC carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -14.1%. By comparison, LCTX (Lineage Cell Therapeutics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $260.5M) and CABA (Cabaletta Bio Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $268.7M). Among the 5-stock peer group, IPSC leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IPSC?

Per IPSC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001850119), Century Therapeutics Inc. generated $109.2M in revenue (+1556.8% YoY), -$9.6M in net income, and -$104.7M in free cash flow against $223.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IPSC trading relative to its 50-day, 200-day, and 52-week technical levels?

IPSC last traded at $1.46 (-2.67% on volume of 1,445,895 shares), positioning the stock -16.09% below its 50-day simple moving average ($1.74) and -30.48% below its 200-day simple moving average ($2.10). Across its 52-week range of $0.44 to $3.04, IPSC sits at the 39.2% percentile with a 14-day RSI of 44.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.28 to $1.64).

IPSC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Century Therapeutics Inc. (IPSC)?

In FY 2025 (10-K), IPSC converted $109.2M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: IPSC RQD Cockpit IPSC 12M Forecast IPSC Earnings & Move IPSC Dividends & DRIP IPSC Insiders & 13F IPSC Whale Options IPSC Profit Sankey IPSC News & Why